Adversomics: A new paradigm for vaccine safety and design

Expert Review of Vaccines

Volumn 14, Issue 7, 2015, Pages 935-947

  Whitaker, Jennifer A ^a   Ovsyannikova, Inna G ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

drug related side effects and adverse reactions; genetic association studies; genomics; immunogenetics; individualized medicine; polymorphism; single nucleotide; systems biology; vaccination; vaccines; viral vaccines

Indexed keywords

ADJUVANT; INFLUENZA VACCINE; SMALLPOX VACCINE; YELLOW FEVER VACCINE; VACCINE;

ADVERSE DRUG REACTION; ADVERSOMICS; AGE; ALLELE; ALLERGIC REACTION; DISEASE PREDISPOSITION; DRUG DESIGN; DRUG INDUCED DISEASE; DRUG SAFETY; GENETIC DIFFERENCE; GENOTYPE PHENOTYPE CORRELATION; GUILLAIN BARRE SYNDROME; HEREDITY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VACCINATION; NARCOLEPSY; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SEIZURE; SEX DIFFERENCE; VACCINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOGENETICS; MEDICAL RESEARCH; PATIENT ATTITUDE; PROCEDURES; SYSTEMS BIOLOGY; TRENDS;

BIOMEDICAL RESEARCH; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOGENETICS; PATIENT ACCEPTANCE OF HEALTH CARE; SYSTEMS BIOLOGY; VACCINES;

EID: 84931830141     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1038249     Document Type: Review

References (122)

1. Centers of Disease Control and Prevention. Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999;48(12):241-3
2. Poland GA, Jacobson RM. The age-old struggle against the antivaccinationists. N Engl J Med 2011;364(2):97-9
3. Tafuri S, Gallone MS, Cappelli MG, et al. Addressing the anti-vaccination movement and the role of HCWs. Vaccine 2014; 32(38):4860-5
4. Poland GA, Jacobson RM. The clinician's guide to the anti-vaccinationists' galaxy. Hum Immunol 2012;73(8):859-66
5. Poland GA, Jacobson RM, Ovsyannikova IG. Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine and consumer culture and vaccinomics. Vaccine 2009; 27(25-26 Special Issue SI):3240-4
6. Larson HJ, Jarrett C, Eckersberger E, et al. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine 2014;32(19): 2150-9
7. Dube E, Gagnon D, Nickels E, et al. Mapping vaccine hesitancy-Country-specific characteristics of a global phenomenon. Vaccine 2014;32(49):6649-54
8. Larson HJ, Smith DM, Paterson P, et al. Measuring vaccine confidence: analysis of data obtained by a media surveillance system used to analyse public concerns about vaccines. Infect Dis 2013;13(7): 606-13
9. Ropeik D. How society should respond to the risk of vaccine rejection. Hum Vaccin Immunother 2013;9(8):1815-18
10. Salmon DA, Moulton LH, Omer SB, et al. Factors associated with refusal of childhood vaccines among parents of school-aged children: a case-control study. Arch Pediat Adolesc Med 2005;159(5):470-6
11. Amanna I, Slifka MK. Public fear of vaccination: separating fact from fiction. Viral Immunol 2005;18(2):307-15
12. Salmon DA, Sotir MJ, Pan WK, et al. Parental vaccine refusal in Wisconsin: a case-control study. WMJ 2009;108(1): 17-23
13. Poland GA, Jacobson RM. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine 2001;19:2440-5
14. Ruggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5675-84
15. Centers for Disease Control and Prevention. In: Vaccine safety. Atkinson W, Wolfe C, Hamborsky J, editors. Epidemiology and prevention of vaccine-preventable diseases. Public Health Foundation; Washington, DC: 2012
16. World Health Organization. Causality Assessment of an Adverse Event Following Immunization (AEFI). 2013. Available from: www.who.int/vaccine-safety/publications/gvs-aefi/en/[Last accessed 4 February 2015]
17. Tozzi AE, Asturias EJ, Balakrishnan MR, et al. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine 2013;31(44):5041-6
18. Poland GA, Kennedy RB, McKinney BA, et al. Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin Immunol 2013;25(2): 89-103
19. Haralambieva IH, Poland GA. Vaccinomics, predictive vaccinology and the future of vaccine development. Future Microbiol 2010;5:1757-60
20. Poland GA, Ovsyannikova IG, Kennedy RB, et al. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. Omics 2011;15(9): 625-36
21. Poland GA, Oberg AL. Vaccinomics and bioinformatics: accelerants for the next golden age of vaccinology. Vaccine 2010; 28(20):3509-10
22. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009;10(5):837-52
23. Poland GA. Pharmacology, vaccinomics, and the second golden age of vaccinology. Clin Pharmacol Ther 2007;82(6):623-6
24. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 2007; 82(6):653-64
25. Poland GA. Vaccidents and adversomics. Vaccine 2010;28(40):6549-50
26. Klein SL, Poland GA. Personalized vaccinology: one size and dose might not fit both sexes. Vaccine 2013;31(23):2599-600
27. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23(10):1603-14
28. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359(9308):727-32
29. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2
30. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43(1): 99-102
31. Mallal S, Phillips E, Carosi G, et al. HLA-B 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6): 568-79
32. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012;109(25): 9959-64
33. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012;486(7404):554-8
34. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B 5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101(12):4180-5
35. Almeida CA, Martin AM, Nolan D, et al. Cytokine profiling in abacavir hypersensitivity patients. Antivir Ther 2008; 13(2):281-8
36. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Last accessed 4 December 2014]
37. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312(4):410-25
38. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008;28(6):822-32
39. Poland GA, Ovsyannikova IG, Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J 2009; 28(5):431-2
40. Verbeek NE, Jansen FE, Vermeer-de Bondt PE, et al. Etiologies for seizures around the time of vaccination. Pediatrics 2014;134(4):658-66
41. Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 2006;5(6):488-92
42. Casey CG, Iskander JK, Roper MH, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005; 294(21):2734-43
43. Poland GA, Neff JM. Smallpox vaccine: problems and prospects. Immunol Allergy Clin North Am 2003;23(4):731-43
44. Reif DM, McKinney BA, Motsinger AA, et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis 2008; 198(1):16-22.
45. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12(3): 183-90
46. El-Khodary NM, El-Haggar SM, Eid MA, Ebeid EN. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2012;29(3):2053-62
47. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005; 23(17-18):2078-81
48. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. Jama 2003;289:3283-9
49. Wilson CB, Marcuse EK. Vaccine safety-vaccine benefits: science and the public's perception. Nat Rev Immunol 2001;1(2): 160-5
50. Ovsyannikova IG, Kennedy RB, O'Byrne M, et al. Genome-wide association study of antibody response to smallpox vaccine. Vaccine 2012;30(28):4182-9
51. Kennedy RB, Ovsyannikova IG, Pankratz VS, et al. Genome-wide genetic associations with IFNgamma response to smallpox vaccine. Hum Genetics 2012; 131(9):1433-51
52. Ovsyannikova IG, Pankrantz VS, Salk HM, et al. HLA alleles associated with the adaptive immune response to smallpox vaccine: a replication study. Hum Genetics 2014;133(9):1083-92
53. Stanley SL Jr, Frey SE, Taillon-Miller P, et al. The immunogenetics of smallpox vaccination. J Infect Dis 2007;196(2): 212-19
54. Lim BK, Choe SC, Shin JO, et al. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 2002;105(11): 1278-81
55. Nakashima H, Miyake K, Inoue Y, et al. Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 2002;3(2):107-9
56. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701-38
57. Ovsyannikova IG, Haralambieva IH, Kennedy RB, et al. Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination. Gene 2012;510:59-65
58. Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008;198(4):500-7
59. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004;22(17-18):2103-5
60. Bae HG, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008;197(11): 1577-84
61. Martins MA, Silva ML, Marciano AP, et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol 2007;148(1):90-100
62. Kwong JC, Vasa PP, Campitelli MA, et al. Risk of Guillain-Barre syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 2013;13(9):769-76
63. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110(2):105-23
64. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barre syndrome following influenza vaccination. JAMA 2004;292(20):2478-81
65. Prasad KN, Nyati KK, Verma A, et al. Tumor necrosis factor-alpha polymorphisms and expression in Guillain-Barre syndrome. Hum Immunol 2010;71(9):905-10
66. Nyati KK, Prasad KN, Verma A, et al. Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-Barre syndrome in Northern Indian population. J Neuroimmunol 2010; 218(1-2):116-19
67. Sang D, Chen Q, Liu X, et al. Fc receptor like 3 in Chinese patients of Han nationality with Guillain-Barre syndrome. J Neuroimmunol 2012;246(1-2):65-8
68. Geleijns K, Emonts M, Laman JD, et al. Genetic polymorphisms of macrophage-mediators in Guillain-Barre syndrome. J Neuroimmunol 2007;190(1-2): 127-30
69. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012;7(3):e33536
70. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012;7(3):e33723
71. Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013;80(14): 1315-21
72. Fontana A, Gast H, Reith W, et al. Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 2010;133(Pt 5):1300-11
73. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007; 369(9560):499-511
74. Hor H, Kutalik Z, Dauvilliers Y, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 2010;42(9):786-9
75. Vaarala O, Vuorela A, Partinen M, et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk. PLoS One 2014;9(12):e114361
76. Julkunen I, Partinen M. Neuroimmunology: disease mechanisms in narcolepsy remain elusive. Nat Rev Neurol 2014;10(11): 616-17
77. Underwood E. Immunology. Key narcolepsy-influenza vaccine findings retracted. Science 2014;345(6196):498
78. Ahmed SS, Schur PH, MacDonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 2014;50:1-11
79. Miller JD, Whitehair LH. Concurrent HLA-related response factors mediate recombinant hepatitis B vaccine major adverse events. Autoimmunity 2005;38(2): 181-94
80. Hohler T, Meyer CU, Notghi A, et al. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol 1998;59(4): 212-18
81. Pan L, Zhang L, Zhang W, et al. A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations. Hum Mol Genet 2014;23(8):2210-19
82. Poland GA, Ovsyannikova IG, Jacobson RM, et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001;20(3-4):430-8
83. St Sauver JL, Ovsyannikova IG, Jacobson RM, et al. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J Infect Dis 2002;185(11):1545-9
84. Ovsyannikova IG, Jacobson RM, Dhiman N, et al. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008;121(5):e1091-9
85. Ovsyannikova IG, Jacobson RM, Vierkant RA, et al. Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine 2009;27(49): 6926-31
86. Pajewski NM, Parker SD, Poland GA, et al. The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed. Genes Immun 2011; 12(6):457-65
87. Ovsyannikova IG, Pankratz VS, Vierkant RA, et al. Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed. Infect Immun 2013;81(7):2584-91
88. Lin Y, He Y. The ontology of genetic susceptibility factors (OGSF) and its application in modeling genetic susceptibility to vaccine adverse events. J Biomed Semantics 2014;5:19
89. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89(4):422-34
90. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009;15(1):34-41
91. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011;239(1):149-66
92. Graham BS, Henderson GS, Tang YW, et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993;151: 2032-40
93. McLellan JS, Correia BE, Chen M, et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol 2011;409(5): 853-66
94. Correia BE, Bates JT, Loomis RJ, et al. Proof of principle for epitope-focused vaccine design. Nature 2014;507(7491): 201-6
95. Cale CM, Klein NJ. The link between rotavirus vaccination and intussusception: implications for vaccine strategies. Gut 2002;50(1):11-12
96. Haber P, Patel M, Pan Y, et al. Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012. Pediatrics 2013;131(6):1042-9
97. Carlin JB, Macartney KK, Lee KJ, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clin Infect Dis 2013;7(10):1427-34
98. Weintraub ES, Baggs J, Duffy J, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med 2014; 70(6):513-19
99. Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination strategies. J Infect Dis 2014;09(Suppl 3): S114-19
100. Beyer WE, Palache AM, Kerstens R, Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis 1996;15(1):65-70
101. Engler RJ, Nelson MR, Klote MM, et al. Half-vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008;168(22):2405-14
102. Weber SK, Schlagenhauf P. Childhood vaccination associated adverse events by sex: a literature review. Travel Med Infect Dis 2014;12(5):459-80
103. Shohat T, Manfred SG, Orly N, et al. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Isr Med Assoc J 2000;2:192-5
104. Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ 1992;304(6834): 1075-8
105. Khalil MK, Al-Mazrou YY, Al-Ghamdi YS, et al. Effect of gender on reporting of MMR adverse events in Saudi Arabia. East Mediterr Health J 2003;9(1-2):152-8
106. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008;26(48): 6077-82
107. Pondo T, Rose CE Jr, Martin SW, et al. Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Vaccine 2014;2(28):3548-54
108. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010;10(5):338-49
109. Umlauf BJ, Haralambieva IH, Ovsyannikova IG, et al. Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination. Viral Immunol 2012;25(1):29-36
110. Ovsyannikova IG, Jacobson RM, Vierkant RA, et al. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol 2004;65:1506-15
111. Chen XQ, Bulbul M, de Gast GC, et al. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. J Hepatol 1997;26(2):260-4
112. Van der Wielen M, Van Damme P, Chlibek R, et al. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006;4(26): 5509-15
113. Bock HL, Kruppenbacher J, Sanger R, et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996; 156(19):2226-31
114. Haralambieva IH, Ovsyannikova IG, Kennedy RB, et al. Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. Hum Immunol 2013;74(10):1263-6
115. Kennedy RB, Ovsyannikova IG, Pankratz VS, et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009;27(25-26):3319-23
116. Doria G, Frasca D. Genetic factors in immunity and aging. Vaccine 2000;18(16): 1591-5
117. Gardner EM, Gonzalez EW, Nogusa S, Murasko DM. Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population. Vaccine 2006;24(10):1609-14
118. Sukumaran L, Mcneil MM, Lewis P, et al. Adverse events following measles, mumps, and rubella (MMR) vaccine in adults reported to the Vaccine Adverse Events Reporting System, 2003-2013. Abstract 1077 ID Week meeting; San Diego, CA; 2014
119. Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001;7(6): 945-51
120. Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200(2):172-80
121. Brighton Collaboration. Immunize Safely. 2015. Available from: https://brightoncollaboration.org/public [Last accessed 4 February 2015]
122. World Health Organization. Global Vaccine Safety Initiative. 2015. Available from: www.who.int/vaccine-safety/en/[Last accessed 4 February 2015]